{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:21:43Z","timestamp":1777954903595,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company (JP)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s10620-016-4100-y","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T06:03:44Z","timestamp":1457503424000},"page":"1888-1894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3683","authenticated-orcid":false,"given":"Jun","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Kogame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Inatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"4100_CR1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","volume":"64","author":"S Shi","year":"2008","unstructured":"Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935\u2013951.","journal-title":"Eur J Clin Pharmacol"},{"key":"4100_CR2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s10620-014-3104-8","volume":"59","author":"G Sachs","year":"2014","unstructured":"Sachs G, Shin JM, Munson K, et al. Gastric acid-dependent diseases: a twentieth-century revolution. Dig Dis Sci. 2014;59:1358\u20131369.","journal-title":"Dig Dis Sci"},{"key":"4100_CR3","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","volume":"126","author":"JM Shin","year":"2004","unstructured":"Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126:7800\u20137811.","journal-title":"J Am Chem Soc"},{"key":"4100_CR4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/13543776.13.5.639","volume":"13","author":"M Tonini","year":"2003","unstructured":"Tonini M, De Giorgio R, De Ponti F. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Pat. 2003;13:639\u2013649.","journal-title":"Expert Opin Ther Pat"},{"key":"4100_CR5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2362.2005.01543.x","volume":"35","author":"J Mossner","year":"2005","unstructured":"Mossner J, Caca K. Developments in the inhibition of gastric acid secretion. Eur J Clin Invest. 2005;35:469\u2013475.","journal-title":"Eur J Clin Invest"},{"key":"4100_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MCG.0b013e31818a386e","volume":"43","author":"CW Howden","year":"2009","unstructured":"Howden CW, Ballard ED, Koch FK, et al. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43:323\u2013326.","journal-title":"J Clin Gastroenterol"},{"key":"4100_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1440-1746.2009.05994.x","volume":"25","author":"R Banerjee","year":"2010","unstructured":"Banerjee R, Reddy DN, Guda NM, et al. Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis. J Gastroenterol Hepatol. 2010;25:43\u201347.","journal-title":"J Gastroenterol Hepatol"},{"key":"4100_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/978-1-4614-3794-9_48","volume-title":"Gastroesophageal reflux disease. Principles of deglutition","author":"D McCarthy","year":"2013","unstructured":"McCarthy D. Gastroesophageal reflux disease. Principles of deglutition. New York: Springer; 2013:693\u2013721."},{"key":"4100_CR9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","volume":"95","author":"U Klotz","year":"2004","unstructured":"Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95:2\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4100_CR10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","volume":"14","author":"PO Katz","year":"2000","unstructured":"Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709\u2013714.","journal-title":"Aliment Pharmacol Ther"},{"key":"4100_CR11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm.2014.20.1.6","volume":"20","author":"C Maradey-Romero","year":"2014","unstructured":"Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20:6.","journal-title":"J Neurogastroenterol Motil"},{"key":"4100_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u2013238.","journal-title":"J Pharmacol Exp Ther"},{"key":"4100_CR13","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm300318t","volume":"55","author":"Y Arikawa","year":"2012","unstructured":"Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446\u20134456.","journal-title":"J Med Chem"},{"key":"4100_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1087057111421004","volume":"17","author":"M Kondo","year":"2012","unstructured":"Kondo M, Kawamoto M, Hasuoka A, et al. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177\u2013182.","journal-title":"J Biomol Screen"},{"key":"4100_CR15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2011.02.009","volume":"81","author":"J Matsukawa","year":"2011","unstructured":"Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145\u20131151.","journal-title":"Biochem Pharmacol"},{"key":"4100_CR16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797\u2013804.","journal-title":"J Pharmacol Exp Ther"},{"key":"4100_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00018-007-7249-x","volume":"65","author":"JM Shin","year":"2008","unstructured":"Shin JM, Vagin O, Munson K, et al. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65:264\u2013281.","journal-title":"Cell Mol Life Sci"},{"key":"4100_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00418-001-0369-8","volume":"117","author":"X Jiang","year":"2002","unstructured":"Jiang X, Suzaki E, Kataoka K. Immunofluorescence detection of gastric H+\/K+-ATPase and its alterations as related to acid secretion. Histochem Cell Biol. 2002;117:21\u201327.","journal-title":"Histochem Cell Biol"},{"key":"4100_CR19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1572-0241.2006.00998.x","volume":"102","author":"DC Metz","year":"2007","unstructured":"Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642\u2013653.","journal-title":"Am J Gastroenterol"},{"key":"4100_CR20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","volume":"108","author":"K Andersson","year":"2005","unstructured":"Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294\u2013307.","journal-title":"Pharmacol Ther"},{"key":"4100_CR21","doi-asserted-by":"crossref","unstructured":"Matsukura N, Asano G. Anatomy, histology, ultrastructure, stomach, rat. In: Jones TC, Popp JA, Mohr U, editors. Monographs on pathology of laboratory animals. Digestive system. 2nd edn. 1997. p. 343\u2013350.","DOI":"10.1007\/978-3-662-25996-2_52"},{"key":"4100_CR22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1136\/gutjnl-2013-305964","volume":"63","author":"E Choi","year":"2014","unstructured":"Choi E, Roland JT, Barlow BJ, et al. Cell lineage distribution atlas of the human stomach reveals heterogeneous gland populations in the gastric antrum. Gut. 2014;63:1711\u20131720.","journal-title":"Gut"},{"key":"4100_CR23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412\u2013420.","journal-title":"J Pharmacol Exp Ther"},{"key":"4100_CR24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"D Scott","year":"2015","unstructured":"Scott D, Munson K, Marcus E, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42:1315\u20131326.","journal-title":"Aliment Pharmacol Ther"},{"key":"4100_CR25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u2013648.","journal-title":"Aliment Pharmacol Ther"},{"key":"4100_CR26","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4100-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T06:35:28Z","timestamp":1567665328000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4100-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]}}}